Adicet Bio Inc. announced its third quarter 2025 financial results and provided business updates. The company reported raising $74.8 million in net proceeds through an underwritten registered direct offering of equity securities in October 2025, extending its projected cash runway into the second half of 2027. Adicet Bio highlighted positive preliminary safety and efficacy data from its Phase 1 clinical trial of ADI-001 in patients with lupus nephritis (LN) and systemic lupus erythematosus $(SLE)$. As of the August 31, 2025 data cut-off, results showed rapid and sustained reductions in the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K) score and Physician's Global Assessment (PGA), improved renal function, and a favorable safety and tolerability profile. The company plans to request a meeting with the U.S. Food and Drug Administration (FDA) in the first quarter of 2026 to discuss the design of a potentially pivotal ADI-001 trial, with initiation targeted for the second quarter of 2026. Adicet Bio is also enrolling patients in Phase 1 trials across multiple indications, including LN, SLE, systemic sclerosis (SSc), idiopathic inflammatory myopathies $(IIM)$, stiff person syndrome (SPS), and ANCA-associated vasculitis (AAV), with a clinical update for LN, SLE, and SSc expected in the first half of 2026.